AASLD 2016 Comp Review

About the Program

• Program Overview
• Target Audience
• Learning Objectives
• Faculty
• Accreditation Statement
• Credit Designation
• Disclosure of Conflicts of Interest
• Disclosure of Unlabeled Use
• Poster/Presentation Listing
• Disclaimer

Program Overview

The Advances in Chronic Hepatitis C: Management and Treatment program is a comprehensive, independent review of the 67th American Association for the Study of Liver Diseases Annual Meeting (AASLD 2016). This program consists of four components: (1) CME Internet Symposium: AASLD 2016 Expert Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) Comprehensive Expert Review and Discussion of Key Presentations: an on-line, in-depth review of 8 of the key poster/presentations reviewed in the Internet symposium (3) Rapid-Fire Independent Review of AASLD 2016: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (4) From Conference To Clinic: Reviewing And Applying Data From AASLD 2016: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.

The Comprehensive Expert Review and Discussion of Key Presentations part of the program will feature HCV experts reviewing and discussing the most important studies on chronic hepatitis C therapy presented at AASLD 2016. This review and discussion will provide a comprehensive overview of each of the posters and presentations selected. In addition, the faculty will provide unique insights into how knowledgeable experts review and analyze data from AASLD and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at AASLD 2016 and it is not sanctioned by the organizers of AASLD 2016.

Back to Top  

Release Date: November 30, 2016

Expiration Date: November 30, 2017

Estimated time to complete each Poster/Presentation: 15-30 minutes 

Media: Internet

Back to Top 

Faculty

Paul J. Pockros, MD
Head, Division of Gastroenterology/Hepatology
Director, SC Liver Research Consortium
The Scripps Clinic
La Jolla, California

Doug Dieterich, MD

• Consulting Fees: Gilead, BMS, AbbVie, Janssen
• Fees for Non-CME/CE Services: Gilead, BMS, AbbVie, Janssen
• Contracted Research: Gilead, BMS, AbbVie, Janssen

Paul Kwo, MD

• Consulting Fees: Abbott, Abbvie, Quest, CVS, BMS, Gilead, Janssen, Merck, Alnylam
• Contracted Research: Abbvie, BMS, Gilead, Janssen, Merck,Conatus
• Other (DSMB): Inovio

Paul Pockros, MD

• Consulting Fees: Gilead, BMS, Merck, Abbvie
• Fees for Non-CME/CE Services: Gilead, Merck, Abbvie, BMS
• Contracted Research: Gilead, BMS, Merck, Genfit, Intercept, Medicinova, RMS, Janssen (To Scripps Health)

Juergen Rockstroh, MD

• Consulting Fees: Abbott, Abbvie, Bionor, BMS, Cipla, Gilead, Janssen, Merck, ViiV
• Fees for Non-CME/CE Services: Abbvie, BMS, Gilead, Janssen, Merck
• Contracted Research: Gilead

The PIM planners and managers, Trace Hutchison, PharmD,  Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN and Jan Shultz, MSN, RN, CHCP have nothing to disclose.

Disclosure of Unlableled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine, ViralEd, Inc., Merck and Co. and Gilead Sciences Medical Affairs. do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Postgraduate Institute for Medicine, ViralEd, Inc., Merck and Co. and Gilead Sciences Medical Affairs. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Poster/Presentation Listing

	Real-world Outcomes With New HCV Antivirals in HIV/HCV-coinfected Subjects: Madrid Coinfection Registry (Madrid-CoRE) Findings
	Hepatitis B Reactivation Associated with Direct Acting Antiviral Therapy for Hepatitis C: A Review of Spontaneous Post-Marketing Cases
	ENDURANCE-1: Efficacy and Safety of 8- versus 12-week Treatment with ABT-493/ABT-530 in patients with Chronic HCV Genotype 1 Infection
	EXPEDITION-IV: Safety and Efficacy of GLE/PIB in Adults with renal impairment and Chronic Hepatitis C Virus Genotype 1 - 6 Infection
	Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 With or Without Ribavirin in Non-cirrhotic or Cirrhotic Patients with CHC GT1, 2 or 3 Infection (Part B of C-CREST-1 & 2)
	Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 in Cirrhotic or Non-cirrhotic Patients with Chronic HCV GT1 Infection who Previously Failed a Direct-acting Antiviral Regimen (C-SURGE)
	A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/ Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naïve Genotype 1-6  HCV-Infected Patients: The POLARIS-2 Study
	Sofosbuvir/Velpatasvir/Voxilaprevir for 12 Weeks as a Salvage Regimen in NS5A Inhibitor-Experienced Patients with Genotype 1-6 Infection: The Phase 3 POLARIS-1 Study

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.    

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at AASLD 2016 and it is not sanctioned by the organizers of AASLD 2016.

This activity is supported by an independent educational grant from Merck & Co.